Chell Simon D, Witherden Ian R, Dobson Richard R, Moorghen Morganaden, Herman Andrew A, Qualtrough David, Williams Ann C, Paraskeva Christos
Cancer Research UK Colorectal Tumour Biology Research Group, Department of Cellular and Molecular Medicine, Faculty of Medical and Veterinary Science, Bristol University, UK.
Cancer Res. 2006 Mar 15;66(6):3106-13. doi: 10.1158/0008-5472.CAN-05-3702.
Cyclooxygenase-2 and prostaglandin E(2) (PGE(2)) levels are increased in colorectal cancers and a subset of adenomas. PGE(2) signaling through the EP4 receptor has previously been associated with colorectal tumorigenesis. However, changes in EP4 expression during adenoma to carcinoma progression have not been investigated, neither has whether levels of EP4 influence important markers of malignant potential, such as anchorage-independent growth or the tumors growth response to PGE(2). We report using immunohistochemistry that in vivo EP4 receptor protein expression was increased in colorectal cancers (100%) as well as adenomas (36%) when compared with normal colonic epithelium. EP4 expression was also higher in colorectal carcinoma compared with adenoma cell lines and increased with in vitro models of tumor progression. Adenoma (PC/AA/C1 and RG/C2) and carcinoma cell lines (HT29) were growth stimulated by PGE(2) up to 0.5 micromol/L. However, although carcinoma and transformed adenoma (PC/AA/C1SB10C, a transformed derivative of PC/AA/C1) cells remain stimulated by higher doses of PGE(2) (10 micromol/L), the adenoma cell lines were inhibited. Interestingly, enforced expression of EP4 in the adenoma cell line, RG/C2, resulted in stimulation of growth by 10 micromol/L PGE(2) and promoted anchorage-independent growth. Both in vivo and in vitro data from this study suggest that increased EP4 receptor expression is important during colorectal carcinogenesis. We propose that high levels of PGE(2) in a tumor microenvironment would select for cells with increased EP4 expression, and that the EP4 receptor may therefore represent an important target for colorectal cancer prevention and treatment.
环氧化酶-2和前列腺素E2(PGE2)水平在结直肠癌及一部分腺瘤中升高。此前,通过EP4受体的PGE2信号传导与结直肠癌发生有关。然而,尚未研究腺瘤向癌进展过程中EP4表达的变化,也未研究EP4水平是否影响恶性潜能的重要标志物,如不依赖贴壁生长或肿瘤对PGE2的生长反应。我们通过免疫组织化学报告,与正常结肠上皮相比,结直肠癌(100%)以及腺瘤(36%)中体内EP4受体蛋白表达增加。与腺癌细胞系相比,结直肠癌中EP4表达也更高,并且随着肿瘤进展的体外模型而增加。腺癌(PC/AA/C1和RG/C2)和癌细胞系(HT29)在PGE2浓度高达0.5微摩尔/升时生长受到刺激。然而,尽管癌和转化腺瘤(PC/AA/C1SB10C,PC/AA/C1的转化衍生物)细胞在更高剂量的PGE2(10微摩尔/升)刺激下仍有生长,但腺癌细胞系受到抑制。有趣的是,在腺癌细胞系RG/C2中强制表达EP4导致10微摩尔/升PGE2刺激生长,并促进不依赖贴壁生长。本研究的体内和体外数据均表明,EP4受体表达增加在结直肠癌发生过程中很重要。我们提出,肿瘤微环境中高水平的PGE2会选择EP4表达增加的细胞,因此EP4受体可能是结直肠癌预防和治疗的一个重要靶点。